CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Yan'an Affiliated Hospital of Kunming Medical University
- Trial code
- NCT07469371
- Record updated
- 16 April 2026
- Original description
Severe aortic stenosis (AS) is often accompanied by coronary artery disease (CAD). While coronary computed tomography angiography (CCTA) is routinely used before aortic valve replacement (AVR) to evaluate coronary anatomy, it lacks physiological assessment of myocardial ischemia.Read full original descriptionShow less
CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis: A Randomized Controlled Trial
Severe aortic stenosis (AS) is often accompanied by coronary artery disease (CAD). While coronary computed tomography angiography (CCTA) is routinely used before aortic valve replacement (AVR) to evaluate coronary anatomy, it lacks physiological assessment of myocardial ischemia.
This prospective, single-center, randomized controlled trial aims to evaluate whether integrating functional assessment using CT-derived fractional flow reserve (CT-FFR) with CCTA can optimize revascularization decision-making and improve clinical outcomes. A total of 300 severe AS patients scheduled for transcatheter or surgical AVR will be randomly assigned to either the experimental group (revascularization decisions guided by both CCTA and CT-FFR) or the control group (decisions guided by CCTA alone). Participants will be followed up for 1 year to assess major adverse cardiovascular events and other clinical outcomes.
Inclusion: Age >18 years; Severe aortic stenosis confirmed by echocardiography, defined as peak aortic jet velocity (Vmax) ≥4.0 m/s, mean transvalvular gradient ≥40 mmHg, or aortic valve area (AVA) ≤1.0 cm² [or indexed aortic valve area (AVAi) ≤0.6 cm²/m²]; New York Heart Association (NYHA) functional class II or higher; Eligible for both transfemoral transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR); Undergoing preoperative coronary computed tomography angiography (CCTA); Willing to participate in the study and able to provide written informed consent.
Exclusion: Prior prosthetic valve implantation in any cardiac position or prior coronary artery bypass grafting (CABG); Acute myocardial infarction within 30 days before surgery; Clinically diagnosed stroke or transient ischemic attack within 3 months before surgery; Bleeding or coagulation disorders within 3 months before surgery that required hospitalization or blood transfusion or were otherwise clinically significant and would preclude the antiplatelet therapy required in this study; Allergy to prosthetic valve materials or iodinated contrast agents; Contraindication or allergic reaction to anticoagulants or antiplatelet agents, or inability to tolerate required anticoagulant or antiplatelet therapy; Active infective endocarditis or any other active infection; Severe vascular disease precluding safe implantation of a prosthetic valve; Ascending aortic diameter ≥50 mm; Preoperative imaging confirming aortic root anatomy unsuitable for transcatheter aortic valve implantation; Intracardiac mass, left ventricular or left atrial thrombus, or vegetation confirmed by preoperative echocardiography.